Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20394132 | 0.83 | NR3C1 (0.33) | PRMT5WDR77 | |
| SCHEMBL3151793 | 0.74 | PRMT5 (0.32) | GAAMAPTPRMT5WDR77BRAF | |
| SCHEMBL3151800 | 0.74 | BRAF (0.37) | GAAMAPTPRMT5WDR77BRAF | |
| SCHEMBL21623709 | 0.74 | PRMT5 (0.32) | GAAMAPTPRMT5WDR77BRAF | |
| SCHEMBL20380147 | 0.74 | BRAF (0.37) | GAAMAPTPRMT5WDR77BRAF | |
| SCHEMBL5496005 | 0.74 | MAPT (0.34) | GAAMAPTPRMT5WDR77BRAF | |
| SCHEMBL997527 | 0.74 | PRMT5 (0.35) | GAAMAPTPRMT5WDR77BRAF | |
| SCHEMBL9610915 | 0.71 | BRAF (0.33) | GAAMAPTPRMT5WDR77BRAF | |
| SCHEMBL22323377 | 0.70 | PDE2A (0.35) | GAAMAPTBRAFPARP1TP53 | |
| SCHEMBL24345788 | 0.69 | PRMT5 (0.40) | PRMT5WDR77BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036750-A | Imidazo [1,2-a ] pyrazine derivative and preparation method and application thereof | 河北科技大学 | 2026-05-15 | — | — | CN | claimed |
| CN-122036750-A | Imidazo [1,2-a ] pyrazine derivative and preparation method and application thereof | 河北科技大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| WO-2025007863-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-119241532-A | 1H-pyrazolo [4,3-c ] pyridine compound, composition and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | DRAIG THERAPEUTICS LTD (GB) | 2024-12-26 | — | — | US | disclosed |
| CN-118684667-A | Compounds for the treatment of fasciolopsis | 默克专利股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20100069361-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| EP-2118097-A1 | 1-OXA-3-AZASPIRO[4,5]DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1973545-A2 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2008092888-A1 | 1-OXA-3-AZASPIRO[4,5]DECAN--2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092891-A1 | 1-OXA-3-AZASPIRO(4.5)DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| WO-2007075869-A2 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1307456-A1 | IMIDAZO-PYRAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010170-A1 | IMIDAZO-PYRAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069361-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | JAK1, MTOR, MOK | GAA 1343/4885MAPT 1997/4885PRMT5 2293/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | GAA 1284/4885MAPT 2300/4885PRMT5 1056/4885 |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | GABRA5, GABRB3, GABRA3 | GAA 1976/4885MAPT 1383/4885PRMT5 1027/4885 |
| US-20090042897-A1 | Chemical Compounds | NPY5R, NPY1R, NPY2R | GAA 659/4885MAPT 2401/4885PRMT5 109/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | GAA 1784/4885MAPT 2333/4885PRMT5 854/4885 |
| US-12215105-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | GAA 905/4885MAPT 3895/4885PRMT5 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.